Founders Fund VI Management’s Cyclo Therapeutics, Inc. Common Stock CYTH Stock Holding History

Founders Fund VI Management’s Portfolio CYTH Stock Details CYTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-110,023	Closed	-$64.9K	–	2
2024 Q4	$64.9K	Hold	110,023	–	–	100%	1
2024 Q3	$86.8K	Hold	110,023	–	–	100%	1
2024 Q2	$140K	Hold	110,023	–	–	100%	1
2024 Q1	$153K	Hold	110,023	–	–	57.89%	1
2023 Q4	$175K	Buy	+110,023	New	+$140K	1.37%	2

Founders Fund VI Management's CYTH Position: Q1 2025 in Review

Founders Fund VI Management sold out of Cyclo Therapeutics, Inc. Common Stock (CYTH) in Q1 2025, closing a stake of 110,023 shares — an estimated $64.9K sold.

Founders Fund VI Management first reported a position in CYTH in Q4 2023 and held it in 5 quarters. The position peaked at $175K in Q4 2023. 0 funds tracked by Wall St. Rank hold CYTH as of Q1 2025.

Founders Fund VI Management reported no remaining Cyclo Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Founders Fund VI Management sold 110,023 Cyclo Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $64.9K.
Founders Fund VI Management first reported a position in Cyclo Therapeutics, Inc. Common Stock in Q4 2023 and held it in 5 quarters.
Founders Fund VI Management's Cyclo Therapeutics, Inc. Common Stock position peaked at $175K in Q4 2023.
0 funds tracked by Wall St. Rank held Cyclo Therapeutics, Inc. Common Stock as of Q1 2025.

Based on Founders Fund VI Management's 13F filing for Q1 2025, filed 15 May 2025.